Kalaris Therapeutics (KLRS) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
LeonaBio (LONA) has outperformed Kalaris Therapeutics (KLRS) over the past year, gaining 46.7% versus a loss of 49.0%. Over five years, LONA leads with a -94.0% price change compared with -99.5% for KLRS. Kalaris Therapeutics is the larger company by market cap ($56.2 million vs $54.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | LONA |
|---|---|---|
| Share price | $2.36 | $5.75 |
| Market cap | $56.18M | $54.17M |
| 1-day change | -5.60% | 0.00% |
| YTD return | -72.04% | -24.04% |
| 1-year return | -48.97% | +46.68% |
| 5-year return | -99.54% | -93.99% |
| EPS (TTM) | $-2.02 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.88 | $14.21 |
| 52-week low | $2.35 | $2.21 |
| Distance from 52-week high | -80.13% | -59.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +692.80% | +201.39% |
| Average volume | 254.36K | 185.88K |
| Shares outstanding | 23.80M | 9.42M |
| Employees | 20 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed KLRS by 95.7 percentage points over the past year.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
KLRS vs LONA FAQ
Which is bigger, Kalaris Therapeutics or LeonaBio?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $56.18M compared with $54.17M for LeonaBio (LONA).
Which stock has performed better over the past year, KLRS or LONA?
LONA returned +46.68% over the past 12 months, compared with -48.97% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Kalaris Therapeutics and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.